- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04641299
A Study of AZD8233 in Participants With Dyslipidemia
A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia
Study Overview
Detailed Description
This is a randomized parallel, double-blind, placebo-controlled, dose-ranging Phase 2b study in approximately 108 participants with dyslipidemia. The primary objective of the study is to investigate the effect of AZD8233 on LDL-C across different dose levels. The study will be conducted at up to 25 sites in up to 4 countries.
The screening period starts up to 42 days before the randomization visit and ends on Day -1. Eligible participants will attend 7 visits during the treatment period and 7 additional visits during the safety follow up period. Eligible participants are randomized across four different treatment arms in a 1:1:1:1 ratio for a 12-week treatment period. The planned treatment arms are AZD8233 low dose, AZD8233 medium dose, AZD8233 high dose, and Placebo. Participants will be dosed SC on Days 1, 8, 29, and 57.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Aarhus N, Denmark, 8200
- Research Site
-
Frederiksberg, Denmark, 2000
- Research Site
-
Herlev, Denmark, 2730
- Research Site
-
Roskilde, Denmark, 4000
- Research Site
-
Viborg, Denmark, 8800
- Research Site
-
-
-
-
-
Bratislava, Slovakia, 831 03
- Research Site
-
Bratislava, Slovakia, 85101
- Research Site
-
Rožňava, Slovakia, 048 01
- Research Site
-
Trebišov, Slovakia, 7501
- Research Site
-
-
-
-
California
-
Roseville, California, United States, 95661
- Research Site
-
-
Florida
-
Inverness, Florida, United States, 34452
- Research Site
-
Jacksonville, Florida, United States, 32216
- Research Site
-
Pembroke Pines, Florida, United States, 33024
- Research Site
-
-
Idaho
-
Meridian, Idaho, United States, 83646
- Research Site
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Research Site
-
-
New York
-
New Windsor, New York, United States, 12553
- Research Site
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27408
- Research Site
-
-
North Dakota
-
Fargo, North Dakota, United States, 58104
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Male or female.
- Participant must be 18 to 75 years of age.
- Body mass index between 19 and 40 kg/m2.
- Participants who have a fasting LDL-C ≥ 70 mg/dL but < 190 mg/dL.
- Have fasting triglycerides < 400 mg/dL.
- Should be receiving moderate- or high-intensity statin therapy.
- Should be on stable medication for ≥ 3 months prior to screening with no planned medication or dose change during study participation. The exception to this restriction is for fenofibrate; if the participant is receiving fenofibrate, the therapy must be stable for at least 6 weeks prior to randomization at a dose that is appropriate for the duration of the study in the judgement of the Investigator. Other fibrate therapy (and derivatives) are prohibited.
Key Exclusion Criteria:
- Estimated glomerular filtration rate < 40 mL/min/1.73m2 CKD-EPI.
- Any uncontrolled or serious disease, or any medical dysfunction or surgical condition that, in the opinion of the Investigator, may either interfere with participation in the clinical study and/or put the participant at significant risk.
- Poorly controlled type 2 diabetes mellitus, defined as HbA1c > 10% at Visit 1.
- Acute ischaemic cardiovascular event in the last 12 months prior to randomization.
- Heart failure with New York Heart Association (NYHA) Class III-IV.
- High-risk of bleeding as judged by the Investigator.
- Malignancy (except non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal
- Carcinoma in-situ, or Stage 1 prostate carcinoma) within the last 10 years.
- LDL or plasma apheresis within 12 months prior to randomization.
- Uncontrolled hypertension defined as average supine SBP > 160 mmHg or DBP > 90 mmHg at Visit 1 or Visit 3.
- Heart rate after 10 minutes supine rest < 50 bpm or > 100 bpm.
Any laboratory values with the following deviations at Screening:
- Positive result on screening for hepatitis B, hepatitis C or HIV.
- ALT > 1.5 × ULN.
- AST > 1.5 × ULN.
- TBL > ULN.
- ALP > 1.5 × ULN.
- WBC < LLN.
- Haemoglobin < 12 g/dL in men or < 11 g/dL in women.
- Platelet count ≤ LLN.
- aPTT > ULN and PT > ULN.
- UACR > 11.3 mg/mmol (100 mg/g).
- UPCR > 300 mg/g.
- Any clinically important abnormalities in rhythm, conduction or morphology of the resting ECG and any clinically important abnormalities in the 12-lead ECG as judged by the Investigator.
- Mipomersen, or lomitapide within 12 months prior to randomization.
- Previous administration of AZD8233/AZD6615.
- Previous administration of PCSK9 inhibition treatment.
- Participation in another clinical study with a study intervention administered in the last 3 months prior to randomization or 5 half-lives from last dose to first administration of study intervention, whichever is the longest.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Placebo solution for subcutaneous injection.
|
Placebo solution
|
Experimental: AZD8233 high dose
AZD8233 high dose for subcutaneous injection.
|
PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
|
Experimental: AZD8233 medium dose
AZD8233 medium dose for subcutaneous injection.
|
PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
|
Experimental: AZD8233 low dose
AZD8233 low does for subcutaneous injection.
|
PCSK9-targeted ASO for the reduction of circulating levels of LDL-C.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12.
Time Frame: Baseline to week 12
|
Change from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12. Results are based on Mixed Model Repeated Measures (MMRM) analysis on the log-transformed change from baseline.
Log-transformed change from baseline is calculated as the visit value in log minus the baseline value in log.
The results from the model are then back transformed.
|
Baseline to week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative Change From Baseline in PCSK9 Concentration in Plasma at Week 12.
Time Frame: Baseline to week 12
|
Relative change from baseline in PCSK9 concentration in plasma at week 12.
|
Baseline to week 12
|
Percentage Change From Baseline in Concentration of TC, HDL-C, Non-HDL-C, VLDL-C, ApoA1, ApoB, Lp(a), Triglycerides, Remnants Cholesterol
Time Frame: Baseline to week 12
|
Percentage change from baseline in concentration of TC, HDL-C, Non-HDL-C, VLDL-C, ApoA1, ApoB, Lp(a), Triglycerides, Remnants cholesterol at week 12
|
Baseline to week 12
|
Plasma Concentration of AZD8233
Time Frame: Measurement at week 1, week 4, week 6, week 8, week 10, week 12, week 16, week 20, week 24 after first dose administration.
|
Plasma concentration of AZD8233 after first dose administration
|
Measurement at week 1, week 4, week 6, week 8, week 10, week 12, week 16, week 20, week 24 after first dose administration.
|
Anti-drug Antibodies (ADAs) During the Treatment Period and Follow-up Period
Time Frame: Measurement at week 0, week 1, week 4, week 8, week 12, week 16, week 20, week 24
|
ADA titre results for subjects with positive ADA during the treatment period and follow-up period.
|
Measurement at week 0, week 1, week 4, week 8, week 12, week 16, week 20, week 24
|
Percentage Change From Baseline in Levels of LDL-C in Plasma
Time Frame: Baseline to week 12
|
Percentage change from baseline in levels of LDL-C in plasma from baseline to week 12.
|
Baseline to week 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Subjects With an ECG Determined to be Abnormal and Clinically Significant
Time Frame: Baseline to Week 24
|
Number of subjects with an ECG determined to be abnormal and clinically significant at baseline and end of treatment.
|
Baseline to Week 24
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D7990C00003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyslipidaemia
-
Novartis PharmaceuticalsCompletedDyslipidaemiaJordan, United States, Taiwan
-
Xention LtdCompleted
-
AstraZenecaCompletedDyslipidaemiaCzech Republic
-
AstraZenecaCompletedHypercholesterolemia | Dyslipidaemia
-
GlaxoSmithKlineCompletedDyslipidaemia | DyslipidaemiasGermany, Estonia, Belgium, France, Netherlands, Denmark, Portugal, Norway, Sweden, Lithuania, Finland
-
AstraZenecaCompletedDyslipidaemiaRussian Federation
-
Xention LtdCompleted
-
AstraZenecaCompletedHypercholesterolemia | Dyslipidaemia
-
Novo Nordisk A/SRecruitingHealthy Volunteers | DyslipidaemiaUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States